Skip to main content
. Author manuscript; available in PMC: 2009 Jun 8.
Published in final edited form as: Semin Nephrol. 2008 May;28(3):217–226. doi: 10.1016/j.semnephrol.2008.03.004

Figure 2. AQP2 transgenic mouse models of nephrogenic diabetes insipidus.

Figure 2

A. Targeting strategy for introduction of the T126M mutation into AQP2 gene replacement. Homologous recombination results in replacement of the indicated segment (thick line) of the AQP2 gene by a 1.8-kb neomycin selection cassette flanked by loxP sites. B. (left) Photograph of mice of indicated genotypes at 5 days after birth. (right) Immunoblot of kidney homogenates. C. Urine osmolality in tamoxifen-treated wildtype mice (open circles) and AQP2flox mice (filled circles) given free access to food and water (S.E.). Arrows indicate tamoxifen injections. D. Twenty-four hour urine output in untreated (left) and tamoxifen-treated (right) WT and AQP2flox mice (arrows indicate urine level). Adapted from refs. 27, 28.